[Therapy of systemic sclerosis].
The therapy of systemic sclerosis (SSc) remains a challenge for dermatology, rheumatology, internal medicine, and other disciplines. Organ involvement, above all kidney and lungs, is a key therapeutic issue. The current developments in organ-specific therapy are the main topic of the article. Finally, possibilities of disease-modifying drugs and value of HSCT are discussed.
Meurer
M
M
Dermatologie am Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. Michael.Meurer@uniklinikum-dresden.de
Rehberger
P
P
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000628:therapy; D005355:Fibrosis; D005385:Fingers / Q000098:blood supply; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006976:Hypertension, Pulmonary / Q000628:therapy; D016285:Iloprost / Q000627:therapeutic use; D016030:Kidney Transplantation; D011701:PUVA Therapy; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D011928:Raynaud Disease / Q000175:diagnosis / Q000628:therapy; D012008:Recurrence; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000628:therapy*; D000068677:Sildenafil Citrate; D012883:Skin Ulcer / Q000175:diagnosis / Q000628:therapy; D013450:Sulfones / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D014665:Vasodilator Agents / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D005765:Gastrointestinal Agents; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D016285:Iloprost